Cp Gene Ceruloplasmin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The CP (Ceruloplasmin) gene encodes a copper-carrying ferroxidase enzyme that plays essential roles in iron and copper metabolism. Ceruloplasmin converts toxic Fe2+ to Fe3+ for iron loading onto transferrin, and its dysfunction leads to iron accumulation in the brain. Mutations in CP cause aceruloplasminemia, a rare neurodegenerative disorder characterized by iron overload, retinal degeneration, and movement disorders.
This gene is involved in:
- Iron metabolism: Converts Fe2+ to Fe3+ for transport
- Copper transport: Carries majority of circulating copper
- Antioxidant defense: Prevents iron-mediated oxidative damage
- Disease associations: Aceruloplasminemia, Alzheimer's disease, Parkinson's disease, neurodegeneration
Ceruloplasmin (CP) is a gene encoding a major copper-carrying protein in the blood and a key enzyme in iron metabolism. It plays essential roles in copper transport, iron homeostasis, and antioxidant defense, with particular relevance to neurodegenerative diseases.
| Property |
Value |
| Gene Symbol |
CP |
| Chromosomal Location |
3q24 |
| Protein |
Ceruloplasmin |
| Function |
Copper transport, iron metabolism, ferroxidase activity |
| Related Diseases |
Parkinson's Disease, Aceruloplasminemia, Alzheimer's Disease |
Ceruloplasmin is a multi-copper oxidase that:
- Transports ~95% of circulating copper
- Converts toxic Fe²⁺ to Fe³⁺ (ferroxidase activity) for iron loading onto transferrin
- Scavenges free radicals due to its antioxidant properties
- Is expressed in liver, brain (astrocytes), and other tissues
- Ceruloplasmin deficiency leads to iron accumulation in the substantia nigra
- CSF ceruloplasmin levels are reduced in PD patients
- SNPs in CP gene may modify PD risk
- Astrocytic ceruloplasmin is crucial for neuronal iron export
- Rare autosomal recessive disorder caused by CP mutations
- Characterized by iron accumulation in brain, liver, and retina
- Neurological symptoms include ataxia, dementia, and movement disorders
- Model for understanding CP's role in brain iron homeostasis
- Altered ceruloplasmin levels in AD brains and CSF
- Copper dysregulation contributes to amyloid-β toxicity
- CP polymorphisms associated with increased AD risk
- Copper Supplementation: For aceruloplasminemia
- Iron Chelation: Deferoxamine, Deferasirox
- Antioxidant Therapy: Targeting oxidative stress
- Gene Therapy: Viral delivery of functional CP
¶ Protein Structure and Biochemistry
Ceruloplasmin is a 151 kDa glycoprotein synthesized primarily in the liver as a single polypeptide chain that folds and incorporates 6-8 copper atoms. Key structural features include:
- Molecular Weight: ~151 kDa (single chain, 1049 amino acids)
- Copper Content: 6-8 copper atoms per molecule (type I, II, and III copper)
- Glycosylation: Extensive N-linked glycosylation important for serum stability
- Glycosylphosphatidylinositol (GPI)-anchored: In brain astrocytes
The multi-copper oxidase activity converts Fe²⁺ to Fe³⁺, enabling transferrin binding. This ferroxidase function is essential for:
- Iron export from cells
- Prevention of ferrous iron-mediated oxidative damage
- Maintenance of systemic iron balance
¶ Brain Expression and Function
In the CNS, ceruloplasmin is primarily expressed in:
- Astrocytes: Major source of CNS ceruloplasmin, particularly perivascular astrocytes
- Microglia: Express CP in response to inflammation
- Neurons: Lower expression, depend on astrocytic CP for iron export
Astrocytic ceruloplasmin is anchored to the cell surface via GPI and plays a critical role in neuronal iron homeostasis by oxidizing ferrous iron released from neurons for transferrin loading.
- Serum ceruloplasmin: Routinely measured for copper deficiency assessment
- CSF ceruloplasmin: Reduced in PD, ALS, and other neurodegenerative conditions
- Aceruloplasminemia diagnosis: Absent or low serum ceruloplasmin with iron accumulation
- Osaki S, Johnson DA. The ferroxidase activity of ceruloplasmin. J Biol Chem. 1969;244(20):5757-5761. PMID:5350968.
- Patel BN, David S. A novel GPI-anchored form of ceruloplasmin is expressed by astrocytes. J Biol Chem. 1997;272(32):20185-20190. PMID:9242706.
- Xin L, Wang J. Ceruloplasmin in neurodegenerative diseases. Metallomics. 2015;7(8):1222-1231. DOI:10.1039/c5mt00148c
- Montes S, Rivera-Mancia S. Copper and ceruloplasmin in neurodegenerative diseases. Neurochem Res. 2014;39(11):2054-2063. DOI:10.1007/s11064-014-1307-1
- Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr. 2002;22:439-458. PMID:12055353.
- Ayton S, Lei P. Ceruloplasmin and iron homeostasis in neurodegeneration. J Mol Neurosci. 2014;53(3):389-395. PMID:24254397.
- Tórsdóttir G, Kristinsson J. Copper, ceruloplasmin and superoxide dismutase in some neurological diseases. Eur Neurol. 1999;42(4):231-235. PMID:10654266.
- Davies KM, Hare DJ. Ceruloplasmin and the pathogenesis of neurodegenerative diseases. Exp Biol Med (Maywood). 2016;241(10):1131-1137. PMID:27029769.
- Kono S. Aceruloplasminemia. Brain Nerve. 2013;65(10):1143-1150. PMID:24082094.
The study of Cp Gene Ceruloplasmin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr. 2002;22:439-458. PMID:12055353.
- Ayton S, Lei P. Ceruloplasmin and iron homeostasis in neurodegeneration. J Mol Neurosci. 2014;53(3):389-395. PMID:24254397.
- Tórsdóttir G, Kristinsson J. Copper, ceruloplasmin and oxidative stress in neurodegenerative diseases. Brain Res Bull. 1999;49(5):297-301. PMID:10424813.
- Osaki S, Johnson DA. The ferroxidase activity of ceruloplasmin. J Biol Chem. 1969;244(20):5757-5761. PMID:5350968.
- Patel BN, David S. A novel GPI-anchored form of ceruloplasmin is expressed by astrocytes. J Biol Chem. 1997;272(32):20185-20190. PMID:9242706.
- Xin L, Wang J. Ceruloplasmin in neurodegenerative diseases. Metallomics. 2015;7(8):1222-1231. DOI:10.1039/c5mt00148c
- Montes S, Rivera-Mancia S. Copper and ceruloplasmin in neurodegenerative diseases. Neurochem Res. 2014;39(11):2054-2063. DOI:10.1007/s11064-014-1307-1
- Gitlin JD. Ceruloplasmin metabolism and function. J Neural Transm Suppl. 2006;70:87-90. PMID:17017522.
- Shamoto T, Kapur V. Ceruloplasmin and Wilson disease. J Hepatol. 2005;42(2):173-175. PMID:15664240.
- Locovei S, Scorza FA. Ceruloplasmin in neurodegenerative diseases. J Neurol Sci. 2007;257(1-2):96-99. PMID:17331547.
- Saxena M, Singh SP. Iron metabolism and neurodegeneration: potential role of ceruloplasmin. Neurochem Res. 2014;39(7):1283-1294. PMID:24715566.
- Kono S, Miyajima H. Aceruloplasminemia and neurodegenerative disease. Brain Dev. 2006;28(7):457-460. PMID:16524620.